HBIO (44) PRPO (38) EYPT (38) BNGO (36) ⌘ Pro Terminal →

Rapid Micro Biosystems Inc. (Class A) (RPID) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell RPID stock right now?

Rapid Micro Biosystems Inc. (Class A) (RPID) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is RPID's 12-month price target and RQD AI Jury consensus?

RPID's 12-month base price target is $0.75 (range $0.58 to $5.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.79 -1.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Rapid Micro Biosystems Inc. (Class A) (RPID) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $39.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPID)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMOVERSOLD (<32)

27.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.79H: $5

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on RPID

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

18/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like RPID

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RPID)

✓Walkthrough of RPID's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RPID // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.08%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.78H $0.79L $0.70C $0.79VOL 201.6K

RES: $1.66SUP: $0.66SMA50: $1.09SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RPID Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RPID Butterfly Map → + Track RPID →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RPID today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RPID. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RPID today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPID)

Health Care Rank #420 of 1016 ⚔️ HBIO vs RPID Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RPID vs. HBIO, PRPO, EYPT, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapid Micro Biosystems Inc. (Class A) (RPID) ranks #420 by composite RQD confidence (47/100, grade D) and #777 by equity capitalization ($39.6M). Within this direct 5-issuer industry benchmark cohort, RPID leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RPID ACTIVE Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	Benchmark Subject
HBIO Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	/hbio-vs-rpid →
PRPO Precipio Inc.	D-	38/100	—	44.2%	-7.9%	+3.59%	$34.6M	/prpo-vs-rpid →
EYPT EyePoint Inc.	D-	38/100	—	—	-35.0%	+0.69%	$32.8M	/eypt-vs-rpid →
BNGO Bionano Genomics Inc.	D-	36/100	—	46.3%	-35.0%	-0.41%	$16.8M	/bngo-vs-rpid →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001380106

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported GAAP revenue of $33.6M (+19.7% vs. FY2024 revenue of $28.1M , and +49.1% cumulative change since FY2023) , GAAP net income of -$47.1M, operating cash flow of -$31.1M, and free cash flow of -$31.9M (+29.9% YoY). On the balance sheet, RPID closed FY2025 with $74.9M in total assets against $18.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.6M	-$47.1M	-$31.1M	-$31.9M	$74.9M	$18.9M
FY2024 (FY)	2024-12-31	$28.1M	-$46.9M	-$44.2M	-$45.5M	$98.2M	$0
FY2023 (FY)	2023-12-31	$22.5M	-$52.5M	-$45.1M	-$45.1M	—	—

3. RPID Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RPID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.79 (-1.37% 1D, market cap $39.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RPID ranks #420 in composite RQD confidence.

How does RPID compare to HBIO and PRPO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $40.1M) and PRPO (Precipio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RPID?

Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RPID trading relative to its 50-day, 200-day, and 52-week technical levels?

RPID last traded at $0.79 (-1.37% on volume of 192,150 shares), positioning the stock -27.52% below its 50-day simple moving average ($1.09) and -64.73% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.70 to $4.94, RPID sits at the 2.1% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).

RPID Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RPID stock right now?

Rapid Micro Biosystems Inc. (Class A) (RPID) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is RPID's 12-month price target and RQD AI Jury consensus?

RPID's 12-month base price target is $0.75 (range $0.58 to $5.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RPID RQD Cockpit RPID 12M Forecast RPID Earnings & Move RPID Dividends & DRIP RPID Insiders & 13F RPID Whale Options RPID Profit Sankey RPID News & Why